Name | Pirmenol |
---|---|
Synonyms |
2-Pyridinemethanol,a-[3-[(2R,6S)-2,6-dimethyl-1-piperidinyl]propyl]-a-phenyl-,rel-(9CI)
2-Pyridinemethanol,a-[3-(2,6-dimethyl-1-piperidinyl)propyl]-a-phenyl-,cis-(+-) 4-[(2S,6R)-2,6-dimethylpiperidin-1-yl]-1-phenyl-1-pyridin-2-ylbutan-1-ol |
Description | Pirmenol is an orally active antiarrhythmic agent. Pirmenol inhibits IK.ACh (IC50: 0.1 μM) by blocking mAchR. Pirmenol can be used in the research of cardiovascular disease, such as atrial fibrillation[1][2][4]. |
---|---|
Related Catalog | |
Target |
IC50: 0.1 μM (IK.ACh)[1] |
In Vitro | Pirmenol (1 μM) inhibits the IK.ACh induced by carbachol or intracellular loading of GTPg S in in atrial cells[1]. Pirmenol (5 μM) depresses the early part of the plateau and lengthened the final repolarization of the action potentials in ventricular myocytes[3]. Pirmenol (1 μM) prolongs the action potential duration at 90% repolarization in atrial muscles and Purkinje fibers[3]. |
In Vivo | Pirmenol (2.5 and 5 mg/kg, p.o.) is effective against the arrhythmias in conscious, coronary artery ligated dogs[4]. Pirmenol (rats) shows LD50s of 359.9 mg/kg (p.o), 23.6 mg/kg (i.v.)[2]. Pirmenol (mice) shows LD50s of 215.5 mg/kg (p.o), 20.8 mg/kg (i.v.)[2]. Animal Model: Conscious, coronary artery ligated dogs[4] Dosage: Oral administration (p.o.) Administration: 2.5 and 5 mg/kg Result: Restored normal sinus rhythm, and showed a long duration of activity, wide safety margin. |
Density | 1.046g/cm3 |
---|---|
Boiling Point | 499.6ºC at 760 mmHg |
Molecular Formula | C22H30N2O |
Molecular Weight | 338.48600 |
Flash Point | 256ºC |
Exact Mass | 338.23600 |
PSA | 36.36000 |
LogP | 4.29850 |
Index of Refraction | 1.547 |
Precursor 4 | |
---|---|
DownStream 0 |